Trials / Completed
CompletedNCT01945489
OnabotulinumtoxinA (BOTOX®) Treatment for Urinary Incontinence in Patients With Overactive Bladder
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 254 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the efficacy and safety of onabotulinumtoxinA (BOTOX®) compared with placebo, in achieving a 100% reduction in urinary incontinence in patients with overactive bladder (OAB) not properly managed with an anticholinergic.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | onabotulinumtoxinA | OnabotulinumtoxinA (BOTOX®) injected into the detrusor. |
| DRUG | Normal saline | Normal saline (placebo) injected into the detrusor. |
Timeline
- Start date
- 2013-10-28
- Primary completion
- 2016-05-24
- Completion
- 2017-01-05
- First posted
- 2013-09-18
- Last updated
- 2017-11-06
- Results posted
- 2017-11-06
Locations
40 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01945489. Inclusion in this directory is not an endorsement.